Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Group leaders in the Departments of Biochemistry (Profs Christina Redfield, Jason Schnell and John Vakonakis) and Chemistry (Profs. Andy Baldwin and Tim Claridge) have secured support towards upgrading the flagship 950 MHz nuclear magnetic resonance (NMR) spectrometer, housed in Biochemistry.

Funding of close to £500K has been obtained from the Engineering and Physical Sciences Research Council (EPSRC) under the “Very- and Ultra-High field NMR for the physical and life sciences” initiative. The 950 MHz NMR upgrade will include a high-sensitivity 5mm TCI “CryoProbe” and an automated sample changer. This new probe will increase 1H signal-to-noise by a factor of up to 3, allowing more challenging macromolecular systems to be studied. The sample changer will improve throughput by enabling fully automated, round-the-clock data collection. Once upgraded, time on the 950 MHz NMR spectrometer will also be made available to external users from other UK academic institutions and from industry. 

Find out more (Department of Biochemistry website)

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.